MaaT Pharma (FR:MAAT)
:MAAT
Want to see FR:MAAT full AI Analyst Report?
Top Page
MaaT Pharma
(MAAT)
Select Model
Select Model
Rating:45Neutral
Price Target:
€6.50
▲(17.97% Upside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial fundamentals: persistent heavy losses, ongoing cash burn, and a notably weakened balance sheet (higher debt and sharply lower equity). Technicals are also bearish with the stock trading below key moving averages, though oversold readings provide slight support. Valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Revenue growth
Sustained revenue growth to ~€4.5M in 2025 evidences improving commercial traction for a clinical-stage biotech. Over 2-6 months this trend supports continued validation of product-market fit and can underpin scaling investments and partner interest if clinical progress continues.
Negative Factors
Heavy cash burn
Persistent, material negative operating and free cash flow forces ongoing reliance on external financing. Over multiple quarters this elevates dilution and refinancing risk, constrains flexibility for R&D or commercialization pacing, and increases vulnerability to funding market cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Sustained revenue growth to ~€4.5M in 2025 evidences improving commercial traction for a clinical-stage biotech. Over 2-6 months this trend supports continued validation of product-market fit and can underpin scaling investments and partner interest if clinical progress continues.
Read all positive factors
MaaT Pharma (MAAT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€126.69M
Dividend YieldN/A
Average Volume (3M)99.82K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth40.67%
EPS Growth11.49%
CountryFR
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.95
Shares Outstanding18,824,076
10 Day Avg. Volume94,708
30 Day Avg. Volume99,816
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)42.60
Price to Sales (P/S)16.94
P/FCF Ratio-4.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.00Price Target Upside226.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.16
Revenue Forecast (FY)€14.00M
MaaT Pharma Business Overview & Revenue Model
Company Description
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatm...
How the Company Makes Money
null...
MaaT Pharma Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.52M | 3.22M | 2.23M | 1.43M | 972.00K |
| Gross Profit | 1.39M | 1.97M | 784.00K | 1.09M | 806.00K |
| EBITDA | -32.41M | -26.34M | -22.07M | -13.10M | -8.57M |
| Net Income | -31.06M | -28.90M | -19.72M | -13.71M | -9.02M |
Balance Sheet | |||||
| Total Assets | 44.55M | 38.50M | 42.93M | 44.73M | 49.42M |
| Cash, Cash Equivalents and Short-Term Investments | 24.87M | 20.22M | 24.31M | 35.31M | 43.30M |
| Total Debt | 17.44M | 15.96M | 14.07M | 11.36M | 5.81M |
| Total Liabilities | 42.75M | 28.16M | 22.46M | 17.91M | 9.56M |
| Stockholders Equity | 1.80M | 10.34M | 20.47M | 26.81M | 39.86M |
Cash Flow | |||||
| Free Cash Flow | -16.52M | -22.79M | -19.76M | -13.27M | -8.17M |
| Operating Cash Flow | -15.91M | -22.04M | -18.67M | -12.61M | -7.93M |
| Investing Cash Flow | -497.00K | -416.00K | -440.00K | -815.00K | -238.00K |
| Financing Cash Flow | 21.12M | 18.33M | 8.14M | 5.36M | 31.56M |
MaaT Pharma Technical Analysis
Negative
5.51
Price Trends
6.73
Negative
5.87
Negative
5.20
Positive
Market Momentum
-0.35
Positive
37.66
Neutral
18.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Negative. The current price of 5.51 is below the 20-day moving average (MA) of 6.07, below the 50-day MA of 6.73, and above the 200-day MA of 5.20, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 37.66 is Neutral, neither overbought nor oversold. The STOCH value of 18.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:MAAT.
MaaT Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | €1.73B | -12.44 | ― | ― | ― | ― | |
53 Neutral | €235.35M | -4.66 | -30.75% | ― | 66.75% | -103.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €219.03M | -2.10 | -634.16% | ― | 291.43% | 12.24% | |
46 Neutral | €8.58B | -8.89 | ― | ― | ― | ― | |
45 Neutral | €126.69M | -1.26 | ― | ― | 40.67% | 11.49% | |
44 Neutral | €118.13M | -1.31 | -658.91% | ― | -77.92% | 11.11% |
* Healthcare Sector Average
FR:MAAT
MaaT Pharma
6.73
1.27
23.26%
FR:IPH
Innate Pharma SA
1.26
-0.79
-38.48%
FR:ABVX
Abivax SA
107.70
101.53
1645.54%
FR:NANO
Nanobiotix
35.84
32.76
1061.75%
FR:TNG
Transgene
0.79
0.19
31.23%
FR:ALCLS
Cellectis SA
3.25
1.86
134.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.